Prostate Cancer Excellence Forum

Prostate Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Enzalutamide With or Without Ra223 for CRPC Metastatic to the Bone

09/24/2019

David Quinn, MD, discusses the clinical significance of the EORTC PEACE III clinical trial.

David Quinn, MD, discusses the...

09/24/2019

Oncology

Interview

ADT Tied to Alzheimer’s Disease, Dementia in Older Patients With Prostate Cancer

08/07/2019

A study led by Ravishankar Jayadevappa, PhD, showed a link between ADT and risk for Alzheimer’s disease/dementia in patients with prostate cancer.

A study led by Ravishankar...

08/07/2019

Oncology

Videos

David Quinn, MD, on the Significance of the ENZAMET Trial in Metastatic Prostate Cancer

06/25/2019

Dr Quinn discusses the significant outcome of a trial evaluating enzalutamide as first-line therapy for men with metastatic prostate cancer.

Dr Quinn discusses the...

06/25/2019

Oncology

Podcasts

Enzalutamide–ADT Combo significantly Improves PFS in Metastatic Hormone-Sensitive Prostate Cancer

02/26/2019

Andrew J. Armstrong, MD, discusses the findings of his team’s recent study on the use of enzalutamide plus ADT versus ADT alone in patients with metastatic hormone sensitive prostate cancer.

Andrew J. Armstrong, MD,...

02/26/2019

Oncology

Interview

MDT Viable for Patients With Metastatic HSPC Wanting to Defer Systemic Therapy

02/21/2019

Neil R. Parikh, MD, discusses the cost-effectiveness of using MDT in the treatment of patients with oligometastatic HSPC.

Neil R. Parikh, MD, discusses...

02/21/2019

Oncology

Podcasts

Survival Benefits of PARP Inhibitors in Metastatic CRPC Favor BRCA1/2 Over ATM Mutations

02/21/2019

Catherine Handy Marshall, MD, MPH, talks about the different responses to PARP inhibitor therapy seen in patients with metastatic CRPC and BRCA1/2 versus ATM mutations.

Catherine Handy Marshall, MD,...

02/21/2019

Oncology

Podcasts

Apalutamide Significantly Delays Metastasis in SPARTAN Trial of Nonmetastatic CRPC

02/14/2019

Julie N. Graff, MD, discusses the promising results of the SPARTAN clinical trial of apalutamide in patients with nonmetastatic CRPC.

Julie N. Graff, MD, discusses...

02/14/2019

Oncology

Interview

The Ins and Outs of CAR-T Therapy and Combined Treatment Approaches

10/09/2018

Mauro Castellarin, PhD, shared his expert insight on next generation CARs, the barriers to and benefits of CAR-T therapy, and the future outlook of this treatment.

Mauro Castellarin, PhD, shared...

10/09/2018

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology